Patents by Inventor Yoji MURATA

Yoji MURATA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antitumor Agent
    Publication number: 20220106394
    Abstract: Provided is an antitumor agent targeting SIRP?, which inhibits binding between CD47 and SIRP?, the antitumor agent being more effective. The present invention also provides an antitumor agent capable of more effectively exhibiting an antitumor effect when used in combination with an immune checkpoint inhibitor or an antibody drug. The antitumor agent includes as an active ingredient a substance that molecularly targets an IgV domain, which is an extracellular domain of SIRP?. The antitumor agent of the present invention, including as an active ingredient a substance that molecularly targets an IgV domain of SIRP? protein, activates M1-type macrophages, which have cytotoxicity to cancer cells, and immunocompetent cells to provide an effective antitumor effect.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
    Inventors: Takashi MATOZAKI, Yoji MURATA
  • Antitumor Agent
    Publication number: 20190153095
    Abstract: Provided is an antitumor agent targeting SIRP?, which inhibits binding between CD47 and SIRP?, the antitumor agent being more effective. The present invention also provides an antitumor agent capable of more effectively exhibiting an antitumor effect when used in combination with an immune checkpoint inhibitor or an antibody drug. The antitumor agent includes as an active ingredient a substance that molecularly targets an IgV domain, which is an extracellular domain of SIRP?. The antitumor agent of the present invention, including as an active ingredient a substance that molecularly targets an IgV domain of SIRP? protein, activates M1-type macrophages, which have cytotoxicity to cancer cells, and immunocompetent cells to provide an effective antitumor effect.
    Type: Application
    Filed: June 27, 2017
    Publication date: May 23, 2019
    Inventors: Takashi MATOZAKI, Yoji MURATA